Sofinnova Investments’s Cidara Therapeutics CDTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-100,000
Closed -$4.87M 63
2025
Q2
$4.87M Buy
+100,000
New +$2.4M 0.3% 50

Sofinnova Investments's CDTX Position: Q1 2026 in Review

Sofinnova Investments sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 180,265 shares — an estimated $39.8M sold.

Sofinnova Investments first reported a position in CDTX in Q1 2018 and held it in 4 quarters. The position peaked at $39.8M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

  • Sofinnova Investments reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sofinnova Investments sold 180,265 Cidara Therapeutics shares in Q1 2026, an estimated $39.8M.
  • Sofinnova Investments first reported a position in Cidara Therapeutics in Q1 2018 and held it in 4 quarters.
  • Sofinnova Investments's Cidara Therapeutics position peaked at $39.8M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.